tamoxifen 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 2561 | 10540-29-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 20 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.50 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 0.50 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 1.18 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 30, 1977 | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Metastases to bone | 1811.70 | 11.70 | 627 | 39240 | 20392 | 63428763 |
| Malignant neoplasm progression | 1639.79 | 11.70 | 867 | 39000 | 81254 | 63367901 |
| Metastases to liver | 1061.57 | 11.70 | 438 | 39429 | 23201 | 63425954 |
| Metastases to lung | 595.02 | 11.70 | 243 | 39624 | 12507 | 63436648 |
| Metastases to lymph nodes | 509.33 | 11.70 | 192 | 39675 | 7966 | 63441189 |
| Breast cancer recurrent | 490.55 | 11.70 | 159 | 39708 | 4182 | 63444973 |
| Breast cancer metastatic | 434.13 | 11.70 | 191 | 39676 | 11827 | 63437328 |
| Disease progression | 417.48 | 11.70 | 447 | 39420 | 122311 | 63326844 |
| Neoplasm progression | 397.99 | 11.70 | 261 | 39606 | 36167 | 63412988 |
| Osteonecrosis of jaw | 241.57 | 11.70 | 190 | 39677 | 34933 | 63414222 |
| Breast cancer | 238.49 | 11.70 | 216 | 39651 | 48167 | 63400988 |
| Metastasis | 232.00 | 11.70 | 96 | 39771 | 5101 | 63444054 |
| Metastases to central nervous system | 204.62 | 11.70 | 118 | 39749 | 12987 | 63436168 |
| Metastases to spine | 190.26 | 11.70 | 73 | 39794 | 3176 | 63445979 |
| Tumour marker increased | 157.92 | 11.70 | 72 | 39795 | 4843 | 63444312 |
| Uterine polyp | 156.60 | 11.70 | 56 | 39811 | 1994 | 63447161 |
| Endometrial hyperplasia | 153.57 | 11.70 | 45 | 39822 | 835 | 63448320 |
| Hot flush | 147.29 | 11.70 | 171 | 39696 | 50988 | 63398167 |
| Metastases to pleura | 146.86 | 11.70 | 50 | 39817 | 1535 | 63447620 |
| Bone lesion | 145.61 | 11.70 | 72 | 39795 | 5809 | 63443346 |
| Bone disorder | 137.27 | 11.70 | 111 | 39756 | 21215 | 63427940 |
| PIK3CA-activated mutation | 136.96 | 11.70 | 43 | 39824 | 1016 | 63448139 |
| Osteonecrosis | 135.76 | 11.70 | 117 | 39750 | 24413 | 63424742 |
| Second primary malignancy | 127.86 | 11.70 | 73 | 39794 | 7880 | 63441275 |
| Neuropathy peripheral | 125.22 | 11.70 | 242 | 39625 | 113425 | 63335730 |
| Contraindicated product administered | 112.13 | 11.70 | 6 | 39861 | 217642 | 63231513 |
| Metastases to skin | 110.55 | 11.70 | 41 | 39826 | 1622 | 63447533 |
| Acute myeloid leukaemia | 109.82 | 11.70 | 89 | 39778 | 17058 | 63432097 |
| Drug ineffective | 109.21 | 11.70 | 318 | 39549 | 1044447 | 62404708 |
| Hormone receptor positive breast cancer | 109.11 | 11.70 | 31 | 39836 | 513 | 63448642 |
| Hepatic lesion | 104.61 | 11.70 | 54 | 39813 | 4771 | 63444384 |
| Systemic lupus erythematosus | 103.87 | 11.70 | 7 | 39860 | 208911 | 63240244 |
| Metastases to peritoneum | 103.01 | 11.70 | 48 | 39819 | 3394 | 63445761 |
| Sarcoma uterus | 101.29 | 11.70 | 18 | 39849 | 20 | 63449135 |
| Pseudocirrhosis | 101.08 | 11.70 | 31 | 39836 | 676 | 63448479 |
| Glossodynia | 98.60 | 11.70 | 3 | 39864 | 178873 | 63270282 |
| Rheumatoid arthritis | 96.06 | 11.70 | 21 | 39846 | 253798 | 63195357 |
| Endometrial hypertrophy | 96.03 | 11.70 | 25 | 39842 | 292 | 63448863 |
| Therapeutic product effect decreased | 91.72 | 11.70 | 8 | 39859 | 193179 | 63255976 |
| Hysteroscopy | 90.38 | 11.70 | 17 | 39850 | 32 | 63449123 |
| Neutropenia | 90.27 | 11.70 | 278 | 39589 | 174727 | 63274428 |
| Carbohydrate antigen 15-3 increased | 90.05 | 11.70 | 34 | 39833 | 1414 | 63447741 |
| Device related thrombosis | 90.04 | 11.70 | 36 | 39831 | 1749 | 63447406 |
| Joint swelling | 89.67 | 11.70 | 47 | 39820 | 327619 | 63121536 |
| Synovitis | 88.04 | 11.70 | 8 | 39859 | 186910 | 63262245 |
| Bone pain | 87.12 | 11.70 | 137 | 39730 | 54504 | 63394651 |
| Osteolysis | 85.76 | 11.70 | 40 | 39827 | 2834 | 63446321 |
| Metastases to the mediastinum | 85.36 | 11.70 | 25 | 39842 | 463 | 63448692 |
| Palmar-plantar erythrodysaesthesia syndrome | 83.69 | 11.70 | 87 | 39780 | 22928 | 63426227 |
| Death | 81.82 | 11.70 | 456 | 39411 | 373925 | 63075230 |
| Endometrial cancer | 78.40 | 11.70 | 39 | 39828 | 3186 | 63445969 |
| Ascites | 76.14 | 11.70 | 110 | 39757 | 40618 | 63408537 |
| Uterine cancer | 72.23 | 11.70 | 42 | 39825 | 4691 | 63444464 |
| Wound | 71.73 | 11.70 | 9 | 39858 | 163254 | 63285901 |
| Tonsillar disorder | 71.44 | 11.70 | 27 | 39840 | 1126 | 63448029 |
| Pulmonary mass | 70.88 | 11.70 | 79 | 39788 | 22517 | 63426638 |
| Lymphadenopathy | 70.63 | 11.70 | 103 | 39764 | 38355 | 63410800 |
| Recurrent cancer | 66.66 | 11.70 | 30 | 39837 | 1957 | 63447198 |
| Hepatic enzyme increased | 66.61 | 11.70 | 22 | 39845 | 202306 | 63246849 |
| Endometrial atrophy | 65.59 | 11.70 | 14 | 39853 | 62 | 63449093 |
| Lymphoedema | 65.15 | 11.70 | 56 | 39811 | 11636 | 63437519 |
| Nasal disorder | 64.83 | 11.70 | 33 | 39834 | 2831 | 63446324 |
| Metastases to pelvis | 64.58 | 11.70 | 20 | 39847 | 451 | 63448704 |
| Abdominal discomfort | 64.33 | 11.70 | 64 | 39803 | 320821 | 63128334 |
| Nail disorder | 63.86 | 11.70 | 58 | 39809 | 12957 | 63436198 |
| Pleural effusion | 63.64 | 11.70 | 164 | 39703 | 93046 | 63356109 |
| Excessive eye blinking | 61.74 | 11.70 | 25 | 39842 | 1255 | 63447900 |
| Blood uric acid decreased | 61.63 | 11.70 | 22 | 39845 | 779 | 63448376 |
| Ejection fraction decreased | 61.50 | 11.70 | 73 | 39794 | 22259 | 63426896 |
| Maternal exposure during pregnancy | 61.00 | 11.70 | 31 | 39836 | 220031 | 63229124 |
| Maculopathy | 59.91 | 11.70 | 29 | 39838 | 2233 | 63446922 |
| Invasive ductal breast carcinoma | 59.71 | 11.70 | 43 | 39824 | 6915 | 63442240 |
| Acute promyelocytic leukaemia | 58.50 | 11.70 | 22 | 39845 | 905 | 63448250 |
| Swelling | 57.43 | 11.70 | 53 | 39814 | 275325 | 63173830 |
| Endocervical curettage | 57.36 | 11.70 | 9 | 39858 | 0 | 63449155 |
| Eosinophil percentage increased | 56.26 | 11.70 | 22 | 39845 | 1007 | 63448148 |
| Malignant pleural effusion | 56.02 | 11.70 | 29 | 39838 | 2577 | 63446578 |
| Metastatic neoplasm | 54.87 | 11.70 | 34 | 39833 | 4261 | 63444894 |
| Retinopathy | 53.84 | 11.70 | 30 | 39837 | 3089 | 63446066 |
| Infusion related reaction | 52.69 | 11.70 | 46 | 39821 | 245475 | 63203680 |
| Breast mass | 52.59 | 11.70 | 42 | 39825 | 7880 | 63441275 |
| Metastases to chest wall | 52.19 | 11.70 | 18 | 39849 | 575 | 63448580 |
| Hypertriglyceridaemia | 52.16 | 11.70 | 38 | 39829 | 6221 | 63442934 |
| Eastern Cooperative Oncology Group performance status worsened | 52.05 | 11.70 | 22 | 39845 | 1232 | 63447923 |
| Invasive lobular breast carcinoma | 52.01 | 11.70 | 20 | 39847 | 875 | 63448280 |
| Ovarian hyperstimulation syndrome | 51.85 | 11.70 | 32 | 39835 | 3982 | 63445173 |
| Pericarditis | 51.57 | 11.70 | 10 | 39857 | 131569 | 63317586 |
| Disease recurrence | 51.36 | 11.70 | 75 | 39792 | 27955 | 63421200 |
| Left ventricular dilatation | 51.14 | 11.70 | 17 | 39850 | 484 | 63448671 |
| Metastases to thorax | 49.25 | 11.70 | 14 | 39853 | 232 | 63448923 |
| Arthropathy | 49.16 | 11.70 | 45 | 39822 | 234747 | 63214408 |
| Dural arteriovenous fistula | 47.83 | 11.70 | 9 | 39858 | 17 | 63449138 |
| Endometrial thickening | 47.67 | 11.70 | 15 | 39852 | 357 | 63448798 |
| Completed suicide | 47.65 | 11.70 | 16 | 39851 | 145657 | 63303498 |
| Recall phenomenon | 46.81 | 11.70 | 17 | 39850 | 633 | 63448522 |
| Treatment failure | 45.54 | 11.70 | 35 | 39832 | 199008 | 63250147 |
| Product use issue | 45.30 | 11.70 | 43 | 39824 | 220477 | 63228678 |
| Uterine leiomyoma | 45.15 | 11.70 | 41 | 39826 | 9157 | 63439998 |
| Tooth extraction | 45.07 | 11.70 | 43 | 39824 | 10221 | 63438934 |
| Vitreous detachment | 44.85 | 11.70 | 23 | 39844 | 2004 | 63447151 |
| Ovarian cancer | 44.70 | 11.70 | 34 | 39833 | 5942 | 63443213 |
| Hypersensitivity | 44.47 | 11.70 | 72 | 39795 | 292613 | 63156542 |
| Exposure during pregnancy | 44.47 | 11.70 | 21 | 39846 | 155526 | 63293629 |
| Endometriosis | 43.66 | 11.70 | 32 | 39835 | 5288 | 63443867 |
| Acquired gene mutation | 43.33 | 11.70 | 18 | 39849 | 965 | 63448190 |
| Peritoneal disorder | 43.26 | 11.70 | 15 | 39852 | 487 | 63448668 |
| Pleural disorder | 43.18 | 11.70 | 16 | 39851 | 631 | 63448524 |
| Metastases to spinal cord | 42.77 | 11.70 | 11 | 39856 | 122 | 63449033 |
| Lymphangiosis carcinomatosa | 42.77 | 11.70 | 20 | 39847 | 1425 | 63447730 |
| Rash | 42.22 | 11.70 | 195 | 39672 | 560676 | 62888479 |
| Bronchomalacia | 41.08 | 11.70 | 12 | 39855 | 220 | 63448935 |
| Metastases to ovary | 40.68 | 11.70 | 14 | 39853 | 444 | 63448711 |
| Oestradiol abnormal | 40.32 | 11.70 | 9 | 39858 | 51 | 63449104 |
| Vulvovaginal dryness | 39.71 | 11.70 | 24 | 39843 | 2877 | 63446278 |
| Cerebral venous thrombosis | 38.70 | 11.70 | 21 | 39846 | 2053 | 63447102 |
| Breast cancer female | 38.45 | 11.70 | 45 | 39822 | 13514 | 63435641 |
| Nasopharyngitis | 38.19 | 11.70 | 63 | 39804 | 254194 | 63194961 |
| Lymphadenopathy mediastinal | 37.84 | 11.70 | 23 | 39844 | 2785 | 63446370 |
| Pulmonary embolism | 37.55 | 11.70 | 159 | 39708 | 116525 | 63332630 |
| Onycholysis | 37.46 | 11.70 | 19 | 39848 | 1617 | 63447538 |
| Polyneuropathy | 37.41 | 11.70 | 46 | 39821 | 14543 | 63434612 |
| Pneumonia | 37.27 | 11.70 | 154 | 39713 | 456613 | 62992542 |
| Exposed bone in jaw | 36.98 | 11.70 | 23 | 39844 | 2902 | 63446253 |
| Haematotoxicity | 36.91 | 11.70 | 37 | 39830 | 9339 | 63439816 |
| Metastases to muscle | 36.88 | 11.70 | 10 | 39857 | 138 | 63449017 |
| Spinal cord compression | 36.43 | 11.70 | 26 | 39841 | 4122 | 63445033 |
| Reversible cerebral vasoconstriction syndrome | 36.41 | 11.70 | 22 | 39845 | 2636 | 63446519 |
| Condition aggravated | 35.75 | 11.70 | 131 | 39736 | 402086 | 63047069 |
| Drug hypersensitivity | 35.60 | 11.70 | 90 | 39777 | 310597 | 63138558 |
| Sinusitis | 35.13 | 11.70 | 55 | 39812 | 226598 | 63222557 |
| BRAF gene mutation | 34.90 | 11.70 | 8 | 39859 | 52 | 63449103 |
| Radiation necrosis | 34.53 | 11.70 | 12 | 39855 | 392 | 63448763 |
| Endometrial disorder | 34.16 | 11.70 | 14 | 39853 | 725 | 63448430 |
| Radiation skin injury | 34.08 | 11.70 | 15 | 39852 | 928 | 63448227 |
| Portal hypertension | 33.69 | 11.70 | 24 | 39843 | 3795 | 63445360 |
| Hypertransaminasaemia | 33.50 | 11.70 | 30 | 39837 | 6579 | 63442576 |
| Metastases to nervous system | 33.24 | 11.70 | 8 | 39859 | 66 | 63449089 |
| Discomfort | 32.79 | 11.70 | 34 | 39833 | 167340 | 63281815 |
| Menopause | 32.68 | 11.70 | 21 | 39846 | 2804 | 63446351 |
| Psoriatic arthropathy | 31.81 | 11.70 | 9 | 39858 | 91511 | 63357644 |
| Blood creatinine decreased | 31.79 | 11.70 | 27 | 39840 | 5518 | 63443637 |
| Oestrogen receptor assay positive | 31.76 | 11.70 | 12 | 39855 | 500 | 63448655 |
| Neoplasm recurrence | 31.48 | 11.70 | 20 | 39847 | 2618 | 63446537 |
| Metastases to uterus | 31.17 | 11.70 | 8 | 39859 | 88 | 63449067 |
| Bone cancer metastatic | 31.07 | 11.70 | 9 | 39858 | 160 | 63448995 |
| Osteosclerosis | 31.03 | 11.70 | 23 | 39844 | 3865 | 63445290 |
| Vaginal haemorrhage | 30.80 | 11.70 | 59 | 39808 | 27428 | 63421727 |
| Blood phosphorus increased | 30.62 | 11.70 | 21 | 39846 | 3124 | 63446031 |
| Muscle injury | 30.20 | 11.70 | 3 | 39864 | 65342 | 63383813 |
| Endometrial adenocarcinoma | 30.20 | 11.70 | 15 | 39852 | 1221 | 63447934 |
| Menopausal disorder | 30.09 | 11.70 | 7 | 39860 | 49 | 63449106 |
| Blister | 29.46 | 11.70 | 23 | 39844 | 129791 | 63319364 |
| Left ventricular dysfunction | 29.46 | 11.70 | 37 | 39830 | 11951 | 63437204 |
| Jaundice | 29.41 | 11.70 | 60 | 39807 | 29191 | 63419964 |
| Mucosal inflammation | 29.40 | 11.70 | 80 | 39787 | 46848 | 63402307 |
| Malignant neoplasm of pleura | 29.27 | 11.70 | 7 | 39860 | 56 | 63449099 |
| Infection | 28.13 | 11.70 | 64 | 39803 | 229109 | 63220046 |
| Cardiac cirrhosis | 28.06 | 11.70 | 8 | 39859 | 134 | 63449021 |
| Cervical polyp | 27.96 | 11.70 | 9 | 39858 | 231 | 63448924 |
| Hydrothorax | 27.91 | 11.70 | 13 | 39854 | 918 | 63448237 |
| Atrophic vulvovaginitis | 27.80 | 11.70 | 16 | 39851 | 1752 | 63447403 |
| Bone sequestrum | 27.71 | 11.70 | 15 | 39852 | 1459 | 63447696 |
| Uterine dilation and curettage | 27.57 | 11.70 | 13 | 39854 | 944 | 63448211 |
| Tumour invasion | 27.53 | 11.70 | 8 | 39859 | 144 | 63449011 |
| Drug abuse | 27.40 | 11.70 | 6 | 39861 | 72512 | 63376643 |
| Intentional product use issue | 27.36 | 11.70 | 24 | 39843 | 127868 | 63321287 |
| Meningeal disorder | 27.35 | 11.70 | 9 | 39858 | 248 | 63448907 |
| Osteitis condensans | 27.35 | 11.70 | 6 | 39861 | 31 | 63449124 |
| Pain in jaw | 27.10 | 11.70 | 74 | 39793 | 43422 | 63405733 |
| Adenocarcinoma | 27.09 | 11.70 | 19 | 39848 | 2931 | 63446224 |
| Adnexa uteri mass | 26.98 | 11.70 | 11 | 39856 | 562 | 63448593 |
| Metastases to eye | 26.93 | 11.70 | 8 | 39859 | 156 | 63448999 |
| Radiation pneumonitis | 26.71 | 11.70 | 15 | 39852 | 1568 | 63447587 |
| Contusion | 26.65 | 11.70 | 33 | 39834 | 150011 | 63299144 |
| Gingival bleeding | 26.50 | 11.70 | 36 | 39831 | 12551 | 63436604 |
| Central nervous system lesion | 26.41 | 11.70 | 33 | 39834 | 10602 | 63438553 |
| RET gene mutation | 26.38 | 11.70 | 5 | 39862 | 10 | 63449145 |
| Pruritus | 26.36 | 11.70 | 127 | 39740 | 361326 | 63087829 |
| BRCA2 gene mutation | 26.20 | 11.70 | 7 | 39860 | 91 | 63449064 |
| Folliculitis | 26.20 | 11.70 | 6 | 39861 | 70311 | 63378844 |
| Leiomyoma | 26.14 | 11.70 | 10 | 39857 | 431 | 63448724 |
| Porphyria non-acute | 26.08 | 11.70 | 9 | 39858 | 288 | 63448867 |
| Peripheral swelling | 26.06 | 11.70 | 83 | 39784 | 265859 | 63183296 |
| Jaw operation | 25.86 | 11.70 | 12 | 39855 | 840 | 63448315 |
| Tympanic membrane disorder | 25.40 | 11.70 | 8 | 39859 | 191 | 63448964 |
| Cardiomyopathy | 25.17 | 11.70 | 42 | 39825 | 17542 | 63431613 |
| Loss of personal independence in daily activities | 25.05 | 11.70 | 15 | 39852 | 97275 | 63351880 |
| Amenorrhoea | 25.00 | 11.70 | 31 | 39836 | 9883 | 63439272 |
| Therapeutic product effect incomplete | 24.95 | 11.70 | 25 | 39842 | 125031 | 63324124 |
| Alopecia | 24.37 | 11.70 | 119 | 39748 | 337417 | 63111738 |
| Pain | 24.21 | 11.70 | 324 | 39543 | 740304 | 62708851 |
| Metastases to stomach | 24.19 | 11.70 | 8 | 39859 | 224 | 63448931 |
| HER2 positive breast cancer | 24.00 | 11.70 | 9 | 39858 | 367 | 63448788 |
| Mucosal toxicity | 23.93 | 11.70 | 9 | 39858 | 370 | 63448785 |
| Actinomycosis | 23.48 | 11.70 | 12 | 39855 | 1038 | 63448117 |
| Alopecia areata | 23.22 | 11.70 | 14 | 39853 | 1671 | 63447484 |
| Tumour marker decreased | 23.13 | 11.70 | 6 | 39861 | 69 | 63449086 |
| Sequestrectomy | 23.12 | 11.70 | 11 | 39856 | 815 | 63448340 |
| Endometrial cancer stage I | 23.09 | 11.70 | 8 | 39859 | 259 | 63448896 |
| Cerebral haemorrhage | 22.98 | 11.70 | 56 | 39811 | 30673 | 63418482 |
| Hepatic cirrhosis | 22.84 | 11.70 | 49 | 39818 | 24685 | 63424470 |
| Deprescribing error | 22.76 | 11.70 | 5 | 39862 | 26 | 63449129 |
| Fibromyalgia | 22.75 | 11.70 | 11 | 39856 | 80409 | 63368746 |
| Jaw disorder | 22.71 | 11.70 | 22 | 39845 | 5327 | 63443828 |
| Sensory loss | 22.65 | 11.70 | 30 | 39837 | 10208 | 63438947 |
| Breast disorder | 22.55 | 11.70 | 16 | 39851 | 2514 | 63446641 |
| Haemangioma of liver | 22.11 | 11.70 | 12 | 39855 | 1173 | 63447982 |
| Metastases to breast | 21.97 | 11.70 | 8 | 39859 | 300 | 63448855 |
| Neoplasm | 21.87 | 11.70 | 25 | 39842 | 7320 | 63441835 |
| Blood alkaline phosphatase increased | 21.86 | 11.70 | 68 | 39799 | 42899 | 63406256 |
| Malignant neoplasm of choroid | 21.83 | 11.70 | 4 | 39863 | 6 | 63449149 |
| Product dose omission issue | 21.66 | 11.70 | 75 | 39792 | 234238 | 63214917 |
| Ventricular hypokinesia | 21.43 | 11.70 | 20 | 39847 | 4624 | 63444531 |
| Pathological fracture | 21.28 | 11.70 | 27 | 39840 | 8807 | 63440348 |
| Hysterectomy | 21.27 | 11.70 | 28 | 39839 | 9471 | 63439684 |
| Toothache | 21.25 | 11.70 | 41 | 39826 | 19158 | 63429997 |
| Abdominal lymphadenopathy | 21.09 | 11.70 | 10 | 39857 | 735 | 63448420 |
| Blood bilirubin abnormal | 21.05 | 11.70 | 11 | 39856 | 996 | 63448159 |
| Oxygen saturation decreased | 20.99 | 11.70 | 15 | 39852 | 88570 | 63360585 |
| Central nervous system infection | 20.95 | 11.70 | 10 | 39857 | 746 | 63448409 |
| Dental operation | 20.74 | 11.70 | 12 | 39855 | 1327 | 63447828 |
| Protein total decreased | 20.66 | 11.70 | 22 | 39845 | 5955 | 63443200 |
| Arteriovenous malformation | 20.57 | 11.70 | 12 | 39855 | 1348 | 63447807 |
| Skin hypopigmentation | 20.52 | 11.70 | 10 | 39857 | 781 | 63448374 |
| Tumour flare | 20.18 | 11.70 | 8 | 39859 | 380 | 63448775 |
| Fibrous histiocytoma | 20.13 | 11.70 | 9 | 39858 | 578 | 63448577 |
| Ovarian cyst | 20.09 | 11.70 | 36 | 39831 | 15909 | 63433246 |
| Myelodysplastic syndrome | 20.06 | 11.70 | 37 | 39830 | 16717 | 63432438 |
| Blood bilirubin increased | 20.04 | 11.70 | 60 | 39807 | 37080 | 63412075 |
| Hepatic steatosis | 20.01 | 11.70 | 51 | 39816 | 28718 | 63420437 |
| Macular hole | 20.00 | 11.70 | 10 | 39857 | 826 | 63448329 |
| Intentional overdose | 19.71 | 11.70 | 11 | 39856 | 74141 | 63375014 |
| Blood cholesterol increased | 19.68 | 11.70 | 18 | 39849 | 94014 | 63355141 |
| Paraneoplastic syndrome | 19.61 | 11.70 | 9 | 39858 | 614 | 63448541 |
| Performance status decreased | 19.25 | 11.70 | 17 | 39850 | 3661 | 63445494 |
| Gastrointestinal toxicity | 19.19 | 11.70 | 24 | 39843 | 7717 | 63441438 |
| Mobility decreased | 19.14 | 11.70 | 29 | 39838 | 121130 | 63328025 |
| Uterine polypectomy | 19.12 | 11.70 | 3 | 39864 | 0 | 63449155 |
| Ovarian cancer stage IV | 18.94 | 11.70 | 7 | 39860 | 274 | 63448881 |
| Metastases to bone marrow | 18.83 | 11.70 | 8 | 39859 | 454 | 63448701 |
| Therapy partial responder | 18.77 | 11.70 | 28 | 39839 | 10630 | 63438525 |
| Somnolence | 18.75 | 11.70 | 54 | 39813 | 178631 | 63270524 |
| Intestinal metastasis | 18.60 | 11.70 | 6 | 39861 | 155 | 63449000 |
| Platelet count abnormal | 18.51 | 11.70 | 16 | 39851 | 3348 | 63445807 |
| Neutrophilia | 18.48 | 11.70 | 18 | 39849 | 4388 | 63444767 |
| Myalgia | 18.42 | 11.70 | 156 | 39711 | 146373 | 63302782 |
| Activated PI3 kinase delta syndrome | 18.34 | 11.70 | 4 | 39863 | 20 | 63449135 |
| Congestive cardiomyopathy | 18.34 | 11.70 | 21 | 39846 | 6161 | 63442994 |
| Breath odour | 18.27 | 11.70 | 11 | 39856 | 1309 | 63447846 |
| Injection site extravasation | 18.18 | 11.70 | 25 | 39842 | 8816 | 63440339 |
| Skin exfoliation | 18.16 | 11.70 | 64 | 39803 | 43038 | 63406117 |
| Heart rate irregular | 17.99 | 11.70 | 42 | 39825 | 22379 | 63426776 |
| Osteomyelitis | 17.96 | 11.70 | 46 | 39821 | 25974 | 63423181 |
| Aeromonas infection | 17.93 | 11.70 | 5 | 39862 | 77 | 63449078 |
| Carcinoembryonic antigen increased | 17.70 | 11.70 | 12 | 39855 | 1753 | 63447402 |
| Adenomyosis | 17.66 | 11.70 | 8 | 39859 | 530 | 63448625 |
| Visual acuity reduced | 17.64 | 11.70 | 41 | 39826 | 21785 | 63427370 |
| Gastrointestinal haemorrhage | 17.64 | 11.70 | 15 | 39852 | 81161 | 63367994 |
| Portal vein thrombosis | 17.58 | 11.70 | 14 | 39853 | 2616 | 63446539 |
| Lymphangioleiomyomatosis | 17.57 | 11.70 | 6 | 39861 | 186 | 63448969 |
| Cardiotoxicity | 17.56 | 11.70 | 24 | 39843 | 8414 | 63440741 |
| Respiratory tract oedema | 17.56 | 11.70 | 8 | 39859 | 537 | 63448618 |
| Septic shock | 17.54 | 11.70 | 10 | 39857 | 66619 | 63382536 |
| Corneal graft rejection | 17.45 | 11.70 | 4 | 39863 | 26 | 63449129 |
| Breast neoplasm | 17.45 | 11.70 | 11 | 39856 | 1421 | 63447734 |
| Sensory disturbance | 17.39 | 11.70 | 31 | 39836 | 13641 | 63435514 |
| Polypectomy | 17.39 | 11.70 | 9 | 39858 | 799 | 63448356 |
| Oophorectomy | 17.38 | 11.70 | 8 | 39859 | 550 | 63448605 |
| Acute kidney injury | 17.24 | 11.70 | 96 | 39771 | 263319 | 63185836 |
| Corneal degeneration | 17.20 | 11.70 | 5 | 39862 | 90 | 63449065 |
| Weight increased | 17.09 | 11.70 | 95 | 39772 | 260697 | 63188458 |
| Diabetic hyperosmolar coma | 17.07 | 11.70 | 7 | 39860 | 363 | 63448792 |
| Pulmonary radiation injury | 17.04 | 11.70 | 3 | 39864 | 3 | 63449152 |
| Back pain | 16.91 | 11.70 | 246 | 39621 | 263899 | 63185256 |
| Deep vein thrombosis | 16.86 | 11.70 | 100 | 39767 | 83700 | 63365455 |
| Respiratory tract inflammation | 16.77 | 11.70 | 8 | 39859 | 596 | 63448559 |
| Ovarian cancer metastatic | 16.51 | 11.70 | 9 | 39858 | 888 | 63448267 |
| Debridement | 16.47 | 11.70 | 10 | 39857 | 1208 | 63447947 |
| Depressed mood | 16.36 | 11.70 | 59 | 39808 | 40132 | 63409023 |
| Menopausal symptoms | 16.23 | 11.70 | 13 | 39854 | 2448 | 63446707 |
| Cortisol increased | 16.07 | 11.70 | 7 | 39860 | 422 | 63448733 |
| Migraine | 16.07 | 11.70 | 25 | 39842 | 103321 | 63345834 |
| Urticaria | 16.05 | 11.70 | 52 | 39815 | 165750 | 63283405 |
| Uterine haemorrhage | 16.00 | 11.70 | 16 | 39851 | 4025 | 63445130 |
| Invasive breast carcinoma | 16.00 | 11.70 | 8 | 39859 | 661 | 63448494 |
| Acute lymphocytic leukaemia | 15.98 | 11.70 | 13 | 39854 | 2503 | 63446652 |
| Knee arthroplasty | 15.98 | 11.70 | 7 | 39860 | 54199 | 63394956 |
| Hydronephrosis | 15.98 | 11.70 | 26 | 39841 | 10636 | 63438519 |
| Non-alcoholic steatohepatitis | 15.84 | 11.70 | 11 | 39856 | 1670 | 63447485 |
| Fungal disease carrier | 15.75 | 11.70 | 4 | 39863 | 42 | 63449113 |
| Enterocolitis bacterial | 15.70 | 11.70 | 6 | 39861 | 258 | 63448897 |
| Intermenstrual bleeding | 15.68 | 11.70 | 22 | 39845 | 7904 | 63441251 |
| Liver scan abnormal | 15.67 | 11.70 | 4 | 39863 | 43 | 63449112 |
| Diverticulitis | 15.50 | 11.70 | 3 | 39864 | 39554 | 63409601 |
| Disturbance in attention | 15.49 | 11.70 | 56 | 39811 | 38133 | 63411022 |
| Product administered at inappropriate site | 15.38 | 11.70 | 14 | 39853 | 3135 | 63446020 |
| Injection site pain | 15.31 | 11.70 | 37 | 39830 | 129763 | 63319392 |
| Headache | 15.30 | 11.70 | 293 | 39574 | 632948 | 62816207 |
| Libido decreased | 15.30 | 11.70 | 13 | 39854 | 2659 | 63446496 |
| Salpingitis | 15.13 | 11.70 | 6 | 39861 | 285 | 63448870 |
| Atrial thrombosis | 15.06 | 11.70 | 11 | 39856 | 1807 | 63447348 |
| Confusional state | 15.00 | 11.70 | 87 | 39780 | 236293 | 63212862 |
| Encephalopathy | 14.99 | 11.70 | 3 | 39864 | 38617 | 63410538 |
| Wheezing | 14.98 | 11.70 | 23 | 39844 | 95572 | 63353583 |
| Oral pustule | 14.97 | 11.70 | 4 | 39863 | 52 | 63449103 |
| Blood follicle stimulating hormone decreased | 14.97 | 11.70 | 3 | 39864 | 9 | 63449146 |
| Neurotoxicity | 14.94 | 11.70 | 33 | 39834 | 16957 | 63432198 |
| Acarodermatitis | 14.93 | 11.70 | 9 | 39858 | 1074 | 63448081 |
| Periodontitis | 14.81 | 11.70 | 14 | 39853 | 3289 | 63445866 |
| Deafness | 14.81 | 11.70 | 34 | 39833 | 17923 | 63431232 |
| Blood copper increased | 14.73 | 11.70 | 3 | 39864 | 10 | 63449145 |
| Ventricular dysfunction | 14.66 | 11.70 | 13 | 39854 | 2815 | 63446340 |
| Gingivitis | 14.64 | 11.70 | 22 | 39845 | 8407 | 63440748 |
| Blood follicle stimulating hormone increased | 14.55 | 11.70 | 5 | 39862 | 158 | 63448997 |
| Breast cancer in situ | 14.52 | 11.70 | 10 | 39857 | 1498 | 63447657 |
| Adenoid cystic carcinoma | 14.51 | 11.70 | 3 | 39864 | 11 | 63449144 |
| Spinal pain | 14.47 | 11.70 | 28 | 39839 | 13111 | 63436044 |
| Coagulation factor V level decreased | 14.44 | 11.70 | 6 | 39861 | 322 | 63448833 |
| Neutrophil count increased | 14.42 | 11.70 | 32 | 39835 | 16495 | 63432660 |
| Salpingo-oophorectomy bilateral | 14.40 | 11.70 | 5 | 39862 | 163 | 63448992 |
| Nasal dryness | 14.34 | 11.70 | 16 | 39851 | 4565 | 63444590 |
| Hip arthroplasty | 14.29 | 11.70 | 6 | 39861 | 47640 | 63401515 |
| Drug resistance | 14.26 | 11.70 | 39 | 39828 | 22894 | 63426261 |
| Breast cancer stage IV | 14.20 | 11.70 | 11 | 39856 | 1975 | 63447180 |
| Sepsis | 14.15 | 11.70 | 49 | 39818 | 153074 | 63296081 |
| Rapidly progressive osteoarthritis | 14.11 | 11.70 | 3 | 39864 | 13 | 63449142 |
| Red blood cell sedimentation rate increased | 14.08 | 11.70 | 5 | 39862 | 43977 | 63405178 |
| Hydrocephalus | 14.05 | 11.70 | 17 | 39850 | 5283 | 63443872 |
| Injection site erythema | 14.03 | 11.70 | 19 | 39848 | 83155 | 63366000 |
| Purulent discharge | 13.98 | 11.70 | 16 | 39851 | 4690 | 63444465 |
| Chronic hepatic failure | 13.93 | 11.70 | 7 | 39860 | 584 | 63448571 |
| Breast pain | 13.93 | 11.70 | 22 | 39845 | 8776 | 63440379 |
| Atypical femur fracture | 13.87 | 11.70 | 17 | 39850 | 5355 | 63443800 |
| Oesophageal varices haemorrhage | 13.85 | 11.70 | 9 | 39858 | 1225 | 63447930 |
| Myocardial infarction | 13.85 | 11.70 | 26 | 39841 | 99867 | 63349288 |
| Cutaneous sarcoidosis | 13.79 | 11.70 | 6 | 39861 | 361 | 63448794 |
| Oral mucosal hypertrophy | 13.76 | 11.70 | 3 | 39864 | 15 | 63449140 |
| Injection site reaction | 13.74 | 11.70 | 10 | 39857 | 58514 | 63390641 |
| Progesterone receptor assay positive | 13.74 | 11.70 | 6 | 39861 | 364 | 63448791 |
| Madarosis | 13.70 | 11.70 | 13 | 39854 | 3068 | 63446087 |
| Retinal artery occlusion | 13.69 | 11.70 | 10 | 39857 | 1643 | 63447512 |
| Pelvic mass | 13.66 | 11.70 | 9 | 39858 | 1253 | 63447902 |
| Metastases to neck | 13.61 | 11.70 | 4 | 39863 | 75 | 63449080 |
| Hair texture abnormal | 13.59 | 11.70 | 15 | 39852 | 4228 | 63444927 |
| Medication error | 13.54 | 11.70 | 8 | 39859 | 52276 | 63396879 |
| Hypotension | 13.49 | 11.70 | 108 | 39759 | 272496 | 63176659 |
| Varices oesophageal | 13.46 | 11.70 | 13 | 39854 | 3135 | 63446020 |
| Postmenopausal haemorrhage | 13.46 | 11.70 | 11 | 39856 | 2131 | 63447024 |
| Overdose | 13.42 | 11.70 | 33 | 39834 | 115045 | 63334110 |
| Vertebral lesion | 13.38 | 11.70 | 7 | 39860 | 635 | 63448520 |
| Hepatic cancer metastatic | 13.38 | 11.70 | 6 | 39861 | 388 | 63448767 |
| Musculoskeletal chest pain | 13.26 | 11.70 | 36 | 39831 | 21047 | 63428108 |
| Anorectal disorder | 13.19 | 11.70 | 10 | 39857 | 1739 | 63447416 |
| Multiple sclerosis relapse | 13.16 | 11.70 | 7 | 39860 | 48471 | 63400684 |
| Trigger finger | 13.12 | 11.70 | 15 | 39852 | 4393 | 63444762 |
| Papillary thyroid cancer | 12.96 | 11.70 | 11 | 39856 | 2245 | 63446910 |
| Adverse event | 12.91 | 11.70 | 14 | 39853 | 67545 | 63381610 |
| Tooth disorder | 12.90 | 11.70 | 43 | 39824 | 28114 | 63421041 |
| Corneal disorder | 12.86 | 11.70 | 10 | 39857 | 1804 | 63447351 |
| Oestradiol increased | 12.80 | 11.70 | 4 | 39863 | 93 | 63449062 |
| Pneumonia aspiration | 12.76 | 11.70 | 3 | 39864 | 34537 | 63414618 |
| Ocular toxicity | 12.72 | 11.70 | 7 | 39860 | 703 | 63448452 |
| Desmoid tumour | 12.72 | 11.70 | 4 | 39863 | 95 | 63449060 |
| Chronic myeloid leukaemia | 12.70 | 11.70 | 11 | 39856 | 2307 | 63446848 |
| Prescribed overdose | 12.55 | 11.70 | 3 | 39864 | 34150 | 63415005 |
| Type 2 diabetes mellitus | 12.47 | 11.70 | 13 | 39854 | 63855 | 63385300 |
| Breast reconstruction | 12.37 | 11.70 | 5 | 39862 | 250 | 63448905 |
| Intraductal proliferative breast lesion | 12.29 | 11.70 | 12 | 39855 | 2933 | 63446222 |
| Peripheral sensorimotor neuropathy | 12.24 | 11.70 | 9 | 39858 | 1494 | 63447661 |
| Metastases to adrenals | 12.24 | 11.70 | 7 | 39860 | 758 | 63448397 |
| Blood oestrogen increased | 12.23 | 11.70 | 4 | 39863 | 108 | 63449047 |
| Toxicity to various agents | 12.21 | 11.70 | 98 | 39769 | 247152 | 63202003 |
| Arthritis | 12.18 | 11.70 | 35 | 39832 | 115886 | 63333269 |
| Internal fixation of fracture | 12.17 | 11.70 | 7 | 39860 | 766 | 63448389 |
| Blood lactate dehydrogenase increased | 12.14 | 11.70 | 37 | 39830 | 23079 | 63426076 |
| Gastrointestinal disorder | 12.12 | 11.70 | 42 | 39825 | 131197 | 63317958 |
| Blood pressure fluctuation | 12.12 | 11.70 | 7 | 39860 | 46310 | 63402845 |
| Nasal congestion | 12.12 | 11.70 | 14 | 39853 | 65646 | 63383509 |
| Superior sagittal sinus thrombosis | 12.02 | 11.70 | 7 | 39860 | 784 | 63448371 |
| Incorrect dose administered | 11.94 | 11.70 | 12 | 39855 | 59956 | 63389199 |
| Dental caries | 11.91 | 11.70 | 23 | 39844 | 10756 | 63438399 |
| Ovarian granulosa-theca cell tumour | 11.86 | 11.70 | 3 | 39864 | 31 | 63449124 |
| HER2 gene amplification | 11.86 | 11.70 | 3 | 39864 | 31 | 63449124 |
| Cholestasis | 11.80 | 11.70 | 43 | 39824 | 29391 | 63419764 |
| Alanine aminotransferase increased | 11.75 | 11.70 | 108 | 39759 | 103662 | 63345493 |
| Pulmonary hypoplasia | 11.70 | 11.70 | 5 | 39862 | 288 | 63448867 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Metastases to bone | 89.16 | 26.03 | 28 | 1251 | 11942 | 34943710 |
| Carbohydrate antigen 15-3 increased | 63.54 | 26.03 | 9 | 1270 | 69 | 34955583 |
| Metastases to lung | 53.86 | 26.03 | 18 | 1261 | 9302 | 34946350 |
| Metastases to central nervous system | 36.35 | 26.03 | 13 | 1266 | 8192 | 34947460 |
| Breast cancer metastatic | 32.83 | 26.03 | 5 | 1274 | 66 | 34955586 |
| Metastases to the mediastinum | 32.03 | 26.03 | 6 | 1273 | 285 | 34955367 |
| Malignant neoplasm progression | 31.72 | 26.03 | 26 | 1253 | 88020 | 34867632 |
| PIK3CA-activated mutation | 31.02 | 26.03 | 5 | 1274 | 97 | 34955555 |
| Hepatic lesion | 28.91 | 26.03 | 9 | 1270 | 3703 | 34951949 |
| Encapsulating peritoneal sclerosis | 27.81 | 26.03 | 6 | 1273 | 583 | 34955069 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Metastases to bone | 1327.15 | 12.46 | 459 | 31004 | 23968 | 79688957 |
| Malignant neoplasm progression | 827.74 | 12.46 | 567 | 30896 | 135423 | 79577502 |
| Metastases to liver | 602.21 | 12.46 | 270 | 31193 | 28044 | 79684881 |
| Metastases to lung | 524.13 | 12.46 | 215 | 31248 | 17948 | 79694977 |
| Breast cancer metastatic | 380.72 | 12.46 | 139 | 31324 | 8463 | 79704462 |
| Breast cancer recurrent | 377.13 | 12.46 | 107 | 31356 | 2870 | 79710055 |
| Metastases to lymph nodes | 376.38 | 12.46 | 145 | 31318 | 10252 | 79702673 |
| Neoplasm progression | 257.16 | 12.46 | 191 | 31272 | 51491 | 79661434 |
| Breast cancer | 243.88 | 12.46 | 157 | 31306 | 33624 | 79679301 |
| Disease progression | 233.76 | 12.46 | 324 | 31139 | 184038 | 79528887 |
| Osteonecrosis of jaw | 195.65 | 12.46 | 151 | 31312 | 43075 | 79669850 |
| Metastases to central nervous system | 177.81 | 12.46 | 99 | 31364 | 16276 | 79696649 |
| Metastases to spine | 158.94 | 12.46 | 61 | 31402 | 4263 | 79708662 |
| Bone lesion | 127.49 | 12.46 | 57 | 31406 | 5862 | 79707063 |
| Hot flush | 123.07 | 12.46 | 129 | 31334 | 54748 | 79658177 |
| Sarcoma uterus | 117.92 | 12.46 | 18 | 31445 | 6 | 79712919 |
| Metastases to skin | 107.27 | 12.46 | 36 | 31427 | 1703 | 79711222 |
| Metastasis | 107.25 | 12.46 | 53 | 31410 | 6827 | 79706098 |
| Tumour marker increased | 104.52 | 12.46 | 45 | 31418 | 4227 | 79708698 |
| Osteonecrosis | 99.73 | 12.46 | 89 | 31374 | 31006 | 79681919 |
| Hepatic lesion | 97.88 | 12.46 | 50 | 31413 | 6909 | 79706016 |
| Neuropathy peripheral | 97.77 | 12.46 | 189 | 31274 | 141116 | 79571809 |
| Endometrial hyperplasia | 94.92 | 12.46 | 26 | 31437 | 610 | 79712315 |
| Second primary malignancy | 94.51 | 12.46 | 63 | 31400 | 14287 | 79698638 |
| Acute myeloid leukaemia | 90.44 | 12.46 | 84 | 31379 | 30801 | 79682124 |
| Carbohydrate antigen 15-3 increased | 87.21 | 12.46 | 28 | 31435 | 1151 | 79711774 |
| PIK3CA-activated mutation | 86.98 | 12.46 | 24 | 31439 | 579 | 79712346 |
| Metastases to the mediastinum | 86.71 | 12.46 | 24 | 31439 | 586 | 79712339 |
| Endometrial cancer | 85.86 | 12.46 | 32 | 31431 | 2062 | 79710863 |
| Device related thrombosis | 85.04 | 12.46 | 34 | 31429 | 2649 | 79710276 |
| Pseudocirrhosis | 84.13 | 12.46 | 24 | 31439 | 656 | 79712269 |
| Metastases to pleura | 83.46 | 12.46 | 29 | 31434 | 1525 | 79711400 |
| Tonsillar disorder | 77.27 | 12.46 | 26 | 31437 | 1240 | 79711685 |
| Breast mass | 76.51 | 12.46 | 42 | 31421 | 6712 | 79706213 |
| Bone disorder | 76.21 | 12.46 | 62 | 31401 | 19051 | 79693874 |
| Lymphadenopathy | 75.57 | 12.46 | 99 | 31364 | 53148 | 79659777 |
| Uterine polyp | 75.32 | 12.46 | 27 | 31436 | 1557 | 79711368 |
| Bone pain | 72.02 | 12.46 | 99 | 31364 | 55643 | 79657282 |
| Endometrial atrophy | 70.40 | 12.46 | 13 | 31450 | 41 | 79712884 |
| Nail disorder | 63.87 | 12.46 | 46 | 31417 | 11806 | 79701119 |
| Metastases to peritoneum | 63.20 | 12.46 | 32 | 31431 | 4340 | 79708585 |
| Lymphoedema | 61.96 | 12.46 | 46 | 31417 | 12367 | 79700558 |
| Nasal disorder | 61.63 | 12.46 | 30 | 31433 | 3739 | 79709186 |
| Hormone receptor positive breast cancer | 59.43 | 12.46 | 16 | 31447 | 351 | 79712574 |
| Metastases to pelvis | 58.46 | 12.46 | 18 | 31445 | 644 | 79712281 |
| Acute promyelocytic leukaemia | 58.27 | 12.46 | 22 | 31441 | 1469 | 79711456 |
| Blood uric acid decreased | 57.67 | 12.46 | 21 | 31442 | 1267 | 79711658 |
| Metastases to chest wall | 57.51 | 12.46 | 17 | 31446 | 528 | 79712397 |
| Invasive lobular breast carcinoma | 57.19 | 12.46 | 18 | 31445 | 693 | 79712232 |
| Maculopathy | 57.01 | 12.46 | 26 | 31437 | 2799 | 79710126 |
| Osteolysis | 56.62 | 12.46 | 30 | 31433 | 4468 | 79708457 |
| Uterine cancer | 56.24 | 12.46 | 28 | 31435 | 3663 | 79709262 |
| Completed suicide | 55.98 | 12.46 | 14 | 31449 | 245753 | 79467172 |
| Pulmonary mass | 55.89 | 12.46 | 63 | 31400 | 28971 | 79683954 |
| Excessive eye blinking | 55.46 | 12.46 | 22 | 31441 | 1679 | 79711246 |
| Retinopathy | 54.85 | 12.46 | 28 | 31435 | 3863 | 79709062 |
| Eosinophil percentage increased | 54.31 | 12.46 | 21 | 31442 | 1497 | 79711428 |
| Mucosal toxicity | 51.66 | 12.46 | 16 | 31447 | 584 | 79712341 |
| Eastern Cooperative Oncology Group performance status worsened | 51.33 | 12.46 | 22 | 31441 | 2043 | 79710882 |
| Ejection fraction decreased | 50.16 | 12.46 | 65 | 31398 | 34512 | 79678413 |
| Recurrent cancer | 48.79 | 12.46 | 23 | 31440 | 2670 | 79710255 |
| Endometrial thickening | 48.34 | 12.46 | 13 | 31450 | 284 | 79712641 |
| Disease recurrence | 47.69 | 12.46 | 72 | 31391 | 44037 | 79668888 |
| Joint swelling | 46.72 | 12.46 | 28 | 31435 | 288618 | 79424307 |
| Vitreous detachment | 46.25 | 12.46 | 21 | 31442 | 2238 | 79710687 |
| Left ventricular dilatation | 45.78 | 12.46 | 17 | 31446 | 1084 | 79711841 |
| Recall phenomenon | 45.25 | 12.46 | 17 | 31446 | 1120 | 79711805 |
| Metastases to eye | 44.93 | 12.46 | 12 | 31451 | 255 | 79712670 |
| Neutropenia | 44.73 | 12.46 | 228 | 31235 | 287482 | 79425443 |
| Bronchomalacia | 44.50 | 12.46 | 12 | 31451 | 265 | 79712660 |
| Endometrial hypertrophy | 44.30 | 12.46 | 11 | 31452 | 173 | 79712752 |
| Lymphangiosis carcinomatosa | 44.02 | 12.46 | 20 | 31443 | 2134 | 79710791 |
| Reversible cerebral vasoconstriction syndrome | 43.09 | 12.46 | 22 | 31441 | 3035 | 79709890 |
| Cerebral venous thrombosis | 42.29 | 12.46 | 21 | 31442 | 2732 | 79710193 |
| Contraindicated product administered | 42.18 | 12.46 | 6 | 31457 | 157532 | 79555393 |
| Therapeutic product effect decreased | 42.14 | 12.46 | 7 | 31456 | 163856 | 79549069 |
| Synovitis | 42.14 | 12.46 | 5 | 31458 | 150729 | 79562196 |
| Hypertriglyceridaemia | 41.90 | 12.46 | 37 | 31426 | 12703 | 79700222 |
| Breast cancer female | 41.16 | 12.46 | 35 | 31428 | 11426 | 79701499 |
| Lymphadenopathy mediastinal | 40.80 | 12.46 | 24 | 31439 | 4372 | 79708553 |
| Peritoneal disorder | 40.57 | 12.46 | 14 | 31449 | 721 | 79712204 |
| Pleural disorder | 40.37 | 12.46 | 15 | 31448 | 958 | 79711967 |
| Rheumatoid arthritis | 40.13 | 12.46 | 16 | 31447 | 208454 | 79504471 |
| BRCA2 gene mutation | 39.73 | 12.46 | 9 | 31454 | 93 | 79712832 |
| Uterine leiomyoma | 39.35 | 12.46 | 27 | 31436 | 6416 | 79706509 |
| Pulmonary embolism | 38.72 | 12.46 | 152 | 31311 | 171502 | 79541423 |
| Acute kidney injury | 38.65 | 12.46 | 93 | 31370 | 519311 | 79193614 |
| Pneumonia | 37.68 | 12.46 | 134 | 31329 | 660112 | 79052813 |
| Metastases to ovary | 37.08 | 12.46 | 11 | 31452 | 346 | 79712579 |
| Invasive ductal breast carcinoma | 36.72 | 12.46 | 25 | 31438 | 5867 | 79707058 |
| Adnexa uteri mass | 36.01 | 12.46 | 11 | 31452 | 383 | 79712542 |
| Palmar-plantar erythrodysaesthesia syndrome | 35.70 | 12.46 | 54 | 31409 | 33080 | 79679845 |
| Endometrial adenocarcinoma | 35.38 | 12.46 | 14 | 31449 | 1061 | 79711864 |
| Ovarian cancer | 35.26 | 12.46 | 21 | 31442 | 3913 | 79709012 |
| Menopause | 35.18 | 12.46 | 17 | 31446 | 2085 | 79710840 |
| Oestradiol abnormal | 34.86 | 12.46 | 7 | 31456 | 38 | 79712887 |
| Vaginal haemorrhage | 34.79 | 12.46 | 43 | 31420 | 21774 | 79691151 |
| Radiation necrosis | 34.69 | 12.46 | 11 | 31452 | 434 | 79712491 |
| Menopausal disorder | 34.55 | 12.46 | 7 | 31456 | 40 | 79712885 |
| Endometriosis | 33.98 | 12.46 | 20 | 31443 | 3648 | 79709277 |
| Ascites | 33.92 | 12.46 | 85 | 31378 | 75477 | 79637448 |
| Systemic lupus erythematosus | 33.91 | 12.46 | 4 | 31459 | 121145 | 79591780 |
| Pathological fracture | 33.46 | 12.46 | 30 | 31433 | 10507 | 79702418 |
| Drug ineffective | 32.53 | 12.46 | 272 | 31191 | 1080641 | 78632284 |
| Haematotoxicity | 32.15 | 12.46 | 35 | 31428 | 15484 | 79697441 |
| Hepatic enzyme increased | 32.02 | 12.46 | 16 | 31447 | 182594 | 79530331 |
| Vulvovaginal dryness | 31.33 | 12.46 | 16 | 31447 | 2208 | 79710717 |
| Left ventricular dysfunction | 30.62 | 12.46 | 38 | 31425 | 19323 | 79693602 |
| Tooth extraction | 30.44 | 12.46 | 29 | 31434 | 10966 | 79701959 |
| Blood creatinine decreased | 30.38 | 12.46 | 25 | 31438 | 7800 | 79705125 |
| Hypertransaminasaemia | 30.30 | 12.46 | 30 | 31433 | 11894 | 79701031 |
| Radiation pneumonitis | 30.15 | 12.46 | 19 | 31444 | 3914 | 79709011 |
| Osteitis condensans | 30.13 | 12.46 | 6 | 31457 | 31 | 79712894 |
| Glossodynia | 29.97 | 12.46 | 3 | 31460 | 103334 | 79609591 |
| Tympanic membrane disorder | 29.40 | 12.46 | 8 | 31455 | 183 | 79712742 |
| Metastases to thorax | 28.76 | 12.46 | 8 | 31455 | 199 | 79712726 |
| Amenorrhoea | 28.67 | 12.46 | 24 | 31439 | 7668 | 79705257 |
| Exposed bone in jaw | 28.59 | 12.46 | 18 | 31445 | 3702 | 79709223 |
| Cardiomyopathy | 28.35 | 12.46 | 45 | 31418 | 28729 | 79684196 |
| Radiation skin injury | 28.32 | 12.46 | 13 | 31450 | 1421 | 79711504 |
| Pleural effusion | 28.31 | 12.46 | 123 | 31340 | 145139 | 79567786 |
| Sensory loss | 28.14 | 12.46 | 30 | 31433 | 12961 | 79699964 |
| Alopecia areata | 28.14 | 12.46 | 14 | 31449 | 1829 | 79711096 |
| Cardiac cirrhosis | 28.03 | 12.46 | 8 | 31455 | 219 | 79712706 |
| Malignant pleural effusion | 27.61 | 12.46 | 17 | 31446 | 3363 | 79709562 |
| Sepsis | 27.28 | 12.46 | 40 | 31423 | 269388 | 79443537 |
| Tumour marker decreased | 27.14 | 12.46 | 6 | 31457 | 55 | 79712870 |
| Atrophic vulvovaginitis | 26.70 | 12.46 | 12 | 31451 | 1249 | 79711676 |
| Portal hypertension | 26.13 | 12.46 | 22 | 31441 | 7086 | 79705839 |
| Septic shock | 26.07 | 12.46 | 8 | 31455 | 122793 | 79590132 |
| Gastrointestinal haemorrhage | 25.81 | 12.46 | 13 | 31450 | 147706 | 79565219 |
| Arteriovenous malformation | 25.78 | 12.46 | 13 | 31450 | 1748 | 79711177 |
| Wound | 25.71 | 12.46 | 7 | 31456 | 116172 | 79596753 |
| Metastases to uterus | 25.67 | 12.46 | 6 | 31457 | 72 | 79712853 |
| Deprescribing error | 25.41 | 12.46 | 5 | 31458 | 24 | 79712901 |
| Congestive cardiomyopathy | 25.16 | 12.46 | 27 | 31436 | 11753 | 79701172 |
| Osteosclerosis | 25.10 | 12.46 | 17 | 31446 | 3954 | 79708971 |
| Skin toxicity | 25.08 | 12.46 | 23 | 31440 | 8291 | 79704634 |
| Hysteroscopy | 24.92 | 12.46 | 5 | 31458 | 27 | 79712898 |
| Hypersensitivity | 24.58 | 12.46 | 41 | 31422 | 262198 | 79450727 |
| Endometrial cancer stage I | 24.51 | 12.46 | 7 | 31456 | 192 | 79712733 |
| Menopausal symptoms | 24.44 | 12.46 | 13 | 31450 | 1950 | 79710975 |
| Myocardial infarction | 24.41 | 12.46 | 22 | 31441 | 184107 | 79528818 |
| Sequestrectomy | 24.15 | 12.46 | 10 | 31453 | 852 | 79712073 |
| Metastatic neoplasm | 23.64 | 12.46 | 18 | 31445 | 5024 | 79707901 |
| Drug abuse | 23.34 | 12.46 | 18 | 31445 | 162673 | 79550252 |
| Breast cancer in situ | 23.26 | 12.46 | 10 | 31453 | 936 | 79711989 |
| Treatment failure | 23.04 | 12.46 | 20 | 31443 | 170466 | 79542459 |
| RET gene mutation | 22.96 | 12.46 | 4 | 31459 | 8 | 79712917 |
| Fibrous histiocytoma | 22.40 | 12.46 | 9 | 31454 | 710 | 79712215 |
| Porphyria non-acute | 22.04 | 12.46 | 9 | 31454 | 740 | 79712185 |
| Hepatic steatosis | 21.93 | 12.46 | 47 | 31416 | 37691 | 79675234 |
| Adenomyosis | 21.68 | 12.46 | 7 | 31456 | 293 | 79712632 |
| Oxygen saturation decreased | 21.60 | 12.46 | 12 | 31451 | 129035 | 79583890 |
| Cervical polyp | 21.35 | 12.46 | 6 | 31457 | 155 | 79712770 |
| Invasive breast carcinoma | 21.22 | 12.46 | 8 | 31455 | 532 | 79712393 |
| Gingival bleeding | 21.15 | 12.46 | 29 | 31434 | 16247 | 79696678 |
| Cardiotoxicity | 20.94 | 12.46 | 25 | 31438 | 12214 | 79700711 |
| Lymphangioleiomyomatosis | 20.93 | 12.46 | 6 | 31457 | 167 | 79712758 |
| Leiomyoma | 20.78 | 12.46 | 7 | 31456 | 335 | 79712590 |
| Toothache | 20.74 | 12.46 | 32 | 31431 | 19938 | 79692987 |
| Injection site extravasation | 20.37 | 12.46 | 22 | 31441 | 9647 | 79703278 |
| Hypotension | 20.29 | 12.46 | 97 | 31366 | 440220 | 79272705 |
| Back pain | 20.25 | 12.46 | 196 | 31267 | 303984 | 79408941 |
| Madarosis | 20.15 | 12.46 | 13 | 31450 | 2789 | 79710136 |
| Non-alcoholic steatohepatitis | 20.03 | 12.46 | 12 | 31451 | 2260 | 79710665 |
| Abdominal lymphadenopathy | 19.97 | 12.46 | 10 | 31453 | 1324 | 79711601 |
| Toxicity to various agents | 19.93 | 12.46 | 92 | 31371 | 421448 | 79291477 |
| Gastrointestinal toxicity | 19.86 | 12.46 | 20 | 31443 | 8089 | 79704836 |
| Pain in jaw | 19.75 | 12.46 | 51 | 31412 | 46100 | 79666825 |
| Hepatic cirrhosis | 19.74 | 12.46 | 43 | 31420 | 34863 | 79678062 |
| Tumour invasion | 19.70 | 12.46 | 7 | 31456 | 393 | 79712532 |
| Protein total decreased | 19.70 | 12.46 | 21 | 31442 | 9071 | 79703854 |
| Central nervous system infection | 19.67 | 12.46 | 10 | 31453 | 1367 | 79711558 |
| Therapy partial responder | 19.66 | 12.46 | 29 | 31434 | 17368 | 79695557 |
| Disturbance in attention | 19.58 | 12.46 | 54 | 31409 | 50747 | 79662178 |
| Paraneoplastic syndrome | 19.12 | 12.46 | 9 | 31454 | 1041 | 79711884 |
| Superior sagittal sinus thrombosis | 19.02 | 12.46 | 9 | 31454 | 1054 | 79711871 |
| Meningeal disorder | 19.01 | 12.46 | 7 | 31456 | 436 | 79712489 |
| Multiple organ dysfunction syndrome | 18.97 | 12.46 | 12 | 31451 | 120234 | 79592691 |
| Atypical femur fracture | 18.95 | 12.46 | 16 | 31447 | 5173 | 79707752 |
| Ovarian cyst | 18.68 | 12.46 | 24 | 31439 | 12631 | 79700294 |
| Nasal dryness | 18.60 | 12.46 | 15 | 31448 | 4548 | 79708377 |
| Postmenopausal haemorrhage | 18.54 | 12.46 | 10 | 31453 | 1542 | 79711383 |
| Paraesthesia | 18.46 | 12.46 | 126 | 31337 | 176197 | 79536728 |
| Breast disorder | 18.37 | 12.46 | 11 | 31452 | 2070 | 79710855 |
| Onycholysis | 18.36 | 12.46 | 11 | 31452 | 2072 | 79710853 |
| Product administered at inappropriate site | 18.25 | 12.46 | 14 | 31449 | 3951 | 79708974 |
| Metabolic acidosis | 18.21 | 12.46 | 5 | 31458 | 82524 | 79630401 |
| Deafness | 18.16 | 12.46 | 31 | 31432 | 21006 | 79691919 |
| Spinal cord compression | 18.00 | 12.46 | 17 | 31446 | 6360 | 79706565 |
| Spinal pain | 17.89 | 12.46 | 26 | 31437 | 15366 | 79697559 |
| Metastases to stomach | 17.83 | 12.46 | 6 | 31457 | 286 | 79712639 |
| Bone sequestrum | 17.78 | 12.46 | 9 | 31454 | 1220 | 79711705 |
| Encapsulating peritoneal sclerosis | 17.70 | 12.46 | 8 | 31455 | 843 | 79712082 |
| Cortisol increased | 17.60 | 12.46 | 7 | 31456 | 538 | 79712387 |
| Respiratory tract inflammation | 17.55 | 12.46 | 8 | 31455 | 860 | 79712065 |
| Corneal degeneration | 17.55 | 12.46 | 5 | 31458 | 136 | 79712789 |
| Respiratory tract oedema | 17.50 | 12.46 | 8 | 31455 | 866 | 79712059 |
| Neoplasm recurrence | 17.49 | 12.46 | 14 | 31449 | 4200 | 79708725 |
| Ovarian hyperstimulation syndrome | 17.30 | 12.46 | 13 | 31450 | 3558 | 79709367 |
| Intermenstrual bleeding | 17.21 | 12.46 | 16 | 31447 | 5868 | 79707057 |
| Metastases to meninges | 17.20 | 12.46 | 13 | 31450 | 3588 | 79709337 |
| Breast neoplasm | 17.01 | 12.46 | 8 | 31455 | 924 | 79712001 |
| Pericarditis | 17.00 | 12.46 | 10 | 31453 | 104226 | 79608699 |
| Abdominal discomfort | 16.99 | 12.46 | 47 | 31416 | 250680 | 79462245 |
| Liver scan abnormal | 16.96 | 12.46 | 4 | 31459 | 50 | 79712875 |
| Product use issue | 16.84 | 12.46 | 36 | 31427 | 209786 | 79503139 |
| Vertebral lesion | 16.71 | 12.46 | 7 | 31456 | 614 | 79712311 |
| Performance status decreased | 16.69 | 12.46 | 16 | 31447 | 6097 | 79706828 |
| Acarodermatitis | 16.68 | 12.46 | 9 | 31454 | 1389 | 79711536 |
| Neutrophilia | 16.59 | 12.46 | 18 | 31445 | 7933 | 79704992 |
| Dyspareunia | 16.48 | 12.46 | 10 | 31453 | 1928 | 79710997 |
| Cerebral haemorrhage | 16.31 | 12.46 | 55 | 31408 | 57618 | 79655307 |
| Polyneuropathy | 16.30 | 12.46 | 32 | 31431 | 24119 | 79688806 |
| Arthropathy | 16.30 | 12.46 | 28 | 31435 | 177083 | 79535842 |
| Hydrothorax | 16.27 | 12.46 | 9 | 31454 | 1459 | 79711466 |
| Corneal graft rejection | 16.23 | 12.46 | 4 | 31459 | 61 | 79712864 |
| Central nervous system lesion | 16.15 | 12.46 | 23 | 31440 | 13345 | 79699580 |
| Intentional overdose | 16.14 | 12.46 | 11 | 31452 | 105949 | 79606976 |
| Exposure during pregnancy | 16.08 | 12.46 | 10 | 31453 | 101122 | 79611803 |
| Breast pain | 16.02 | 12.46 | 18 | 31445 | 8247 | 79704678 |
| Skin exfoliation | 15.99 | 12.46 | 53 | 31410 | 55047 | 79657878 |
| Heart rate irregular | 15.98 | 12.46 | 38 | 31425 | 32641 | 79680284 |
| Lower limb fracture | 15.96 | 12.46 | 31 | 31432 | 23184 | 79689741 |
| Ventricular hypokinesia | 15.95 | 12.46 | 19 | 31444 | 9260 | 79703665 |
| Blood phosphorus increased | 15.87 | 12.46 | 20 | 31443 | 10327 | 79702598 |
| Infusion related reaction | 15.72 | 12.46 | 43 | 31420 | 230194 | 79482731 |
| Actinomycosis | 15.62 | 12.46 | 8 | 31455 | 1111 | 79711814 |
| Cardio-respiratory arrest | 15.56 | 12.46 | 12 | 31451 | 108498 | 79604427 |
| Discomfort | 15.49 | 12.46 | 16 | 31447 | 125601 | 79587324 |
| Respiratory failure | 15.40 | 12.46 | 30 | 31433 | 180881 | 79532044 |
| Hair colour changes | 15.35 | 12.46 | 13 | 31450 | 4219 | 79708706 |
| Trigger finger | 15.32 | 12.46 | 13 | 31450 | 4232 | 79708693 |
| Depressed mood | 15.30 | 12.46 | 48 | 31415 | 48432 | 79664493 |
| Hair texture abnormal | 15.23 | 12.46 | 12 | 31451 | 3522 | 79709403 |
| Swelling | 15.15 | 12.46 | 40 | 31423 | 216671 | 79496254 |
| Infection | 15.15 | 12.46 | 47 | 31416 | 241665 | 79471260 |
| Breath odour | 15.06 | 12.46 | 9 | 31454 | 1687 | 79711238 |
| Diabetic hyperosmolar coma | 15.04 | 12.46 | 7 | 31456 | 790 | 79712135 |
| Encephalopathy | 15.02 | 12.46 | 4 | 31459 | 67393 | 79645532 |
| Cutaneous sarcoidosis | 15.01 | 12.46 | 6 | 31457 | 467 | 79712458 |
| Oral mucosal hypertrophy | 14.98 | 12.46 | 3 | 31460 | 16 | 79712909 |
| Psoriatic arthropathy | 14.98 | 12.46 | 6 | 31457 | 77993 | 79634932 |
| Corneal disorder | 14.94 | 12.46 | 10 | 31453 | 2281 | 79710644 |
| Anorectal disorder | 14.93 | 12.46 | 10 | 31453 | 2283 | 79710642 |
| Blood oestrogen increased | 14.89 | 12.46 | 4 | 31459 | 87 | 79712838 |
| Pneumonia aspiration | 14.88 | 12.46 | 4 | 31459 | 66963 | 79645962 |
| Deep vein thrombosis | 14.86 | 12.46 | 90 | 31373 | 120829 | 79592096 |
| Haemangioma of liver | 14.86 | 12.46 | 8 | 31455 | 1230 | 79711695 |
| Blood alkaline phosphatase increased | 14.84 | 12.46 | 57 | 31406 | 63607 | 79649318 |
| Rapidly progressive osteoarthritis | 14.83 | 12.46 | 3 | 31460 | 17 | 79712908 |
| Debridement | 14.82 | 12.46 | 9 | 31454 | 1736 | 79711189 |
| Jaw operation | 14.77 | 12.46 | 7 | 31456 | 822 | 79712103 |
| Mucosal inflammation | 14.72 | 12.46 | 64 | 31399 | 75516 | 79637409 |
| Coma | 14.60 | 12.46 | 11 | 31452 | 100638 | 79612287 |
| Condition aggravated | 14.58 | 12.46 | 127 | 31336 | 500997 | 79211928 |
| Hepatotoxicity | 14.55 | 12.46 | 49 | 31414 | 51303 | 79661622 |
| Blood potassium abnormal | 14.36 | 12.46 | 11 | 31452 | 3099 | 79709826 |
| Breast reconstruction | 14.32 | 12.46 | 4 | 31459 | 101 | 79712824 |
| Oestradiol increased | 14.25 | 12.46 | 4 | 31459 | 103 | 79712822 |
| Adenocarcinoma | 14.23 | 12.46 | 12 | 31451 | 3874 | 79709051 |
| Adenoid cystic carcinoma | 14.16 | 12.46 | 3 | 31460 | 22 | 79712903 |
| Sensory disturbance | 14.06 | 12.46 | 23 | 31440 | 15054 | 79697871 |
| Metastases to breast | 14.02 | 12.46 | 5 | 31458 | 284 | 79712641 |
| Loss of personal independence in daily activities | 13.90 | 12.46 | 12 | 31451 | 102568 | 79610357 |
| Retinal artery occlusion | 13.80 | 12.46 | 11 | 31452 | 3283 | 79709642 |
| Cystoid macular oedema | 13.78 | 12.46 | 9 | 31454 | 1971 | 79710954 |
| Portal vein thrombosis | 13.59 | 12.46 | 14 | 31449 | 5813 | 79707112 |
| Ovarian granulosa-theca cell tumour | 13.52 | 12.46 | 3 | 31460 | 28 | 79712897 |
| Nasopharyngitis | 13.47 | 12.46 | 53 | 31410 | 253828 | 79459097 |
| Chronic hepatic failure | 13.40 | 12.46 | 7 | 31456 | 1012 | 79711913 |
| Coagulation factor V level decreased | 13.34 | 12.46 | 6 | 31457 | 625 | 79712300 |
| Pruritus | 13.34 | 12.46 | 96 | 31367 | 394552 | 79318373 |
| HER2 positive breast cancer | 13.26 | 12.46 | 5 | 31458 | 333 | 79712592 |
| Blood pressure fluctuation | 13.16 | 12.46 | 5 | 31458 | 67140 | 79645785 |
| Enterocolitis bacterial | 13.09 | 12.46 | 6 | 31457 | 653 | 79712272 |
| Unresponsive to stimuli | 13.04 | 12.46 | 3 | 31460 | 55785 | 79657140 |
| Metastases to muscle | 12.95 | 12.46 | 5 | 31458 | 355 | 79712570 |
| Folliculitis | 12.90 | 12.46 | 3 | 31460 | 55377 | 79657548 |
| Carcinoembryonic antigen increased | 12.89 | 12.46 | 9 | 31454 | 2200 | 79710725 |
| Uterine haemorrhage | 12.82 | 12.46 | 10 | 31453 | 2893 | 79710032 |
| Atrial thrombosis | 12.79 | 12.46 | 11 | 31452 | 3645 | 79709280 |
| Aeromonas infection | 12.74 | 12.46 | 5 | 31458 | 371 | 79712554 |
| Atypical fracture | 12.70 | 12.46 | 6 | 31457 | 700 | 79712225 |
| Rhabdomyosarcoma | 12.56 | 12.46 | 4 | 31459 | 160 | 79712765 |
| Gastric infection | 12.54 | 12.46 | 11 | 31452 | 3742 | 79709183 |
| Dental operation | 12.54 | 12.46 | 7 | 31456 | 1155 | 79711770 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | L02BA01 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ENDOCRINE THERAPY HORMONE ANTAGONISTS AND RELATED AGENTS Anti-estrogens |
| FDA MoA | N0000000168 | Selective Estrogen Receptor Modulators |
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D018931 | Antineoplastic Agents, Hormonal |
| MeSH PA | D050071 | Bone Density Conservation Agents |
| MeSH PA | D004965 | Estrogen Antagonists |
| MeSH PA | D020847 | Estrogen Receptor Modulators |
| MeSH PA | D006727 | Hormone Antagonists |
| MeSH PA | D020845 | Selective Estrogen Receptor Modulators |
| FDA EPC | N0000175826 | Estrogen Agonist/Antagonist |
| CHEBI has role | CHEBI:35610 | antineoplastic agents |
| CHEBI has role | CHEBI:37700 | protein kinase C inhibitors |
| CHEBI has role | CHEBI:48422 | angiogenesis antagonist |
| CHEBI has role | CHEBI:50646 | antiosteoporotic |
| CHEBI has role | CHEBI:50792 | estrogen receptor antagonists |
| CHEBI has role | CHEBI:50837 | oestrogen antagonist |
| CHEBI has role | CHEBI:62872 | quinoline oxidase inhibitors |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Infiltrating duct carcinoma of breast | indication | 408643008 | DOID:3008 |
| Carcinoma of female breast | indication | 447782002 | |
| Prevention of Breast Carcinoma | indication | ||
| Pain of breast | off-label use | 53430007 | |
| Endometrial carcinoma | off-label use | 254878006 | DOID:2871 |
| Malignant tumor of ovary | off-label use | 363443007 | DOID:2394 |
| Hypercalcemia | contraindication | 66931009 | DOID:12678 |
| Leukopenia | contraindication | 84828003 | DOID:615 |
| Bilateral cataracts | contraindication | 95722004 | |
| Deep venous thrombosis | contraindication | 128053003 | |
| Cerebrovascular accident | contraindication | 230690007 | |
| Pulmonary thromboembolism | contraindication | 233935004 | |
| Pregnancy, function | contraindication | 289908002 | |
| Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
| Thromboembolic disorder | contraindication | 371039008 | |
| Visual impairment | contraindication | 397540003 | |
| Breastfeeding (mother) | contraindication | 413712001 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.61 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Estrogen receptor | Nuclear hormone receptor | MODULATOR | Ki | 7.51 | CHEMBL | CHEMBL | |||
| Beta-1 adrenergic receptor | GPCR | Ki | 5.00 | DRUG MATRIX | |||||
| Prostaglandin G/H synthase 2 | Enzyme | IC50 | 4.46 | WOMBAT-PK | |||||
| Prostaglandin G/H synthase 1 | Enzyme | IC50 | 5.36 | DRUG MATRIX | |||||
| Mu-type opioid receptor | GPCR | Ki | 5.15 | DRUG MATRIX | |||||
| D(1A) dopamine receptor | GPCR | Ki | 5.37 | DRUG MATRIX | |||||
| D(2) dopamine receptor | GPCR | Ki | 5.34 | DRUG MATRIX | |||||
| Adenosine receptor A2a | GPCR | Ki | 5.40 | DRUG MATRIX | |||||
| Alpha-2A adrenergic receptor | GPCR | Ki | 6.14 | DRUG MATRIX | |||||
| Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 7.50 | WOMBAT-PK | |||||
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 5.80 | CHEMBL | |||||
| 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase | Enzyme | Ki | 8.30 | WOMBAT-PK | |||||
| Multidrug resistance protein 1 | Transporter | Ki | 7 | WOMBAT-PK | |||||
| Sodium-dependent serotonin transporter | Transporter | Ki | 5.91 | DRUG MATRIX | |||||
| Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.84 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | Ki | 5.16 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 2A | GPCR | Ki | 5.86 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 2B | GPCR | Ki | 5.88 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 2C | GPCR | Ki | 6.62 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 6 | GPCR | Ki | 5.98 | CHEMBL | |||||
| Alpha-2B adrenergic receptor | GPCR | Ki | 5.79 | DRUG MATRIX | |||||
| D(3) dopamine receptor | GPCR | Ki | 6.44 | DRUG MATRIX | |||||
| Histamine H2 receptor | GPCR | Ki | 5.03 | DRUG MATRIX | |||||
| Muscarinic acetylcholine receptor M1 | GPCR | Ki | 6.17 | DRUG MATRIX | |||||
| Muscarinic acetylcholine receptor M2 | GPCR | Ki | 5.56 | DRUG MATRIX | |||||
| Muscarinic acetylcholine receptor M3 | GPCR | Ki | 6.20 | DRUG MATRIX | |||||
| Muscarinic acetylcholine receptor M4 | GPCR | Ki | 6.17 | DRUG MATRIX | |||||
| Muscarinic acetylcholine receptor M5 | GPCR | Ki | 5.73 | DRUG MATRIX | |||||
| Aldehyde oxidase | Enzyme | IC50 | 5.66 | WOMBAT-PK | |||||
| Beta-3 adrenergic receptor | GPCR | Ki | 5.24 | DRUG MATRIX | |||||
| Sodium-dependent dopamine transporter | Transporter | Ki | 5.84 | DRUG MATRIX | |||||
| Adenosine receptor A3 | GPCR | Ki | 5.68 | DRUG MATRIX | |||||
| Nuclear receptor subfamily 1 group I member 2 | Nuclear hormone receptor | Ki | 7.46 | WOMBAT-PK | |||||
| D(4) dopamine receptor | GPCR | Ki | 5.41 | DRUG MATRIX | |||||
| Alpha-1D adrenergic receptor | GPCR | Ki | 5.61 | DRUG MATRIX | |||||
| Kappa-type opioid receptor | GPCR | Ki | 5.20 | DRUG MATRIX | |||||
| Progesterone receptor | Nuclear hormone receptor | IC50 | 6.89 | CHEMBL | |||||
| Delta-type opioid receptor | GPCR | Ki | 5.33 | DRUG MATRIX | |||||
| Estrogen receptor beta | Nuclear hormone receptor | IC50 | 5.91 | WOMBAT-PK | |||||
| G-protein coupled estrogen receptor 1 | GPCR | IC50 | 7.50 | WOMBAT-PK | |||||
| Estrogen-related receptor gamma | Nuclear hormone receptor | Ki | 7.10 | WOMBAT-PK | |||||
| Epidermal growth factor receptor | Kinase | IC50 | 5.45 | DRUG MATRIX | |||||
| Substance-P receptor | GPCR | Ki | 5.07 | DRUG MATRIX | |||||
| Tyrosine-protein kinase Lck | Kinase | IC50 | 5.10 | DRUG MATRIX | |||||
| Tyrosine-protein kinase Fyn | Kinase | IC50 | 5.92 | DRUG MATRIX | |||||
| Receptor tyrosine-protein kinase erbB-2 | Kinase | IC50 | 5.53 | DRUG MATRIX | |||||
| Glucosylceramidase | Enzyme | EC50 | 5.60 | CHEMBL | |||||
| Thromboxane-A synthase | Enzyme | IC50 | 6.04 | DRUG MATRIX | |||||
| Steroid hormone receptor ERR1 | Nuclear hormone receptor | IC50 | 6.70 | CHEMBL | |||||
| Substance-K receptor | GPCR | Ki | 5.91 | DRUG MATRIX | |||||
| B2 bradykinin receptor | GPCR | Ki | 4.92 | DRUG MATRIX | |||||
| Melanocortin receptor 4 | GPCR | Ki | 4.53 | DRUG MATRIX | |||||
| Melanocortin receptor 5 | GPCR | Ki | 4.60 | DRUG MATRIX | |||||
| Melanocortin receptor 3 | GPCR | Ki | 4.76 | DRUG MATRIX | |||||
| Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform | Enzyme | IC50 | 4.52 | DRUG MATRIX | |||||
| Solute carrier family 22 member 2 | Transporter | IC50 | 4.06 | WOMBAT-PK | |||||
| Emopamil-binding protein-like | Enzyme | Ki | 8.55 | CHEMBL | |||||
| Anti-estrogen binding site (AEBS) | Enzyme | Kd | 9 | CHEMBL | |||||
| Adenosine receptor A1 | GPCR | Ki | 4.86 | DRUG MATRIX | |||||
| Sodium/potassium-transporting ATPase subunit alpha-2 | Ion channel | IC50 | 4.81 | DRUG MATRIX | |||||
| Androgen receptor | Transcription factor | Ki | 4.82 | DRUG MATRIX | |||||
| Membrane-associated progesterone receptor component 1 | Membrane receptor | Ki | 6.42 | DRUG MATRIX | |||||
| Progesterone receptor | Transcription factor | Ki | 5.59 | DRUG MATRIX | |||||
| Alpha-1A adrenergic receptor | GPCR | IC50 | 4.66 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | IC50 | 4.92 | CHEMBL | |||||
| C-8 sterol isomerase | Enzyme | Ki | 5.82 | CHEMBL | |||||
| Transcriptional activator protein luxR | Unclassified | IC50 | 4.40 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019939 | VUID |
| N0000148024 | NUI |
| D00966 | KEGG_DRUG |
| 54965-24-1 | SECONDARY_CAS_RN |
| 4018462 | VANDF |
| 4019939 | VANDF |
| C0039286 | UMLSCUI |
| CHEBI:41774 | CHEBI |
| CTX | PDB_CHEM_ID |
| CHEMBL83 | ChEMBL_ID |
| DB00675 | DRUGBANK_ID |
| CHEMBL786 | ChEMBL_ID |
| D013629 | MESH_DESCRIPTOR_UI |
| 2733526 | PUBCHEM_CID |
| 1016 | IUPHAR_LIGAND_ID |
| 3299 | INN_ID |
| 094ZI81Y45 | UNII |
| 10324 | RXNORM |
| 2281 | MMSL |
| 4270 | MMSL |
| 5540 | MMSL |
| d00381 | MMSL |
| 002670 | NDDF |
| 004826 | NDDF |
| 373345002 | SNOMEDCT_US |
| 41395001 | SNOMEDCT_US |
| 75959001 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0144 | TABLET | 10 mg | ORAL | ANDA | 26 sections |
| Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0144 | TABLET | 10 mg | ORAL | ANDA | 26 sections |
| Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0144 | TABLET | 10 mg | ORAL | ANDA | 26 sections |
| Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0274 | TABLET | 20 mg | ORAL | ANDA | 26 sections |
| Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0274 | TABLET | 20 mg | ORAL | ANDA | 26 sections |
| Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0274 | TABLET | 20 mg | ORAL | ANDA | 26 sections |
| Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-2472 | TABLET | 10 mg | ORAL | ANDA | 25 sections |
| Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-2472 | TABLET | 10 mg | ORAL | ANDA | 25 sections |
| Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-2473 | TABLET | 20 mg | ORAL | ANDA | 25 sections |
| Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-2473 | TABLET | 20 mg | ORAL | ANDA | 25 sections |
| Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-0485 | TABLET | 10 mg | ORAL | ANDA | 25 sections |
| Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-0485 | TABLET | 10 mg | ORAL | ANDA | 25 sections |
| Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-0942 | TABLET | 20 mg | ORAL | ANDA | 25 sections |
| Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-439 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 28 sections |
| Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-439 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 28 sections |
| Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-439 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 28 sections |
| Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-440 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 28 sections |
| Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-440 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 28 sections |
| Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-440 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 28 sections |
| Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51862-446 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 26 sections |
| Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51862-446 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 26 sections |
| Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51862-447 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 26 sections |
| Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51862-447 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 26 sections |
| Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51862-642 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 28 sections |
| Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51862-642 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 28 sections |
| Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51862-642 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 28 sections |
| Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51862-643 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 28 sections |
| Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51862-643 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 28 sections |
| Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51862-643 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 28 sections |
| SOLTAMOX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51862-682 | LIQUID | 20 mg | ORAL | NDA | 33 sections |